Calcium Imaging in Drug Discovery for Psychiatric Disorders
The past 5 years have seen a sharp increase in the number of studies using calcium imaging in behaving rodents. These studies have helped identify important roles for individual cells, brain regions, and circuits in some of the core behavioral phenotypes of psychiatric disorders, such as schizophren...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2020-07-01
|
| Series: | Frontiers in Psychiatry |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/article/10.3389/fpsyt.2020.00713/full |
| _version_ | 1818445859813064704 |
|---|---|
| author | Saurav Seshadri Daniel J. Hoeppner Katsunori Tajinda |
| author_facet | Saurav Seshadri Daniel J. Hoeppner Katsunori Tajinda |
| author_sort | Saurav Seshadri |
| collection | DOAJ |
| description | The past 5 years have seen a sharp increase in the number of studies using calcium imaging in behaving rodents. These studies have helped identify important roles for individual cells, brain regions, and circuits in some of the core behavioral phenotypes of psychiatric disorders, such as schizophrenia and autism, and have characterized network dysfunction in well-established models of these disorders. Since rescuing clinically relevant behavioral deficits in disease model mice remains a foundation of preclinical CNS research, these studies have the potential to inform new therapeutic approaches targeting specific cell types or projections, or perhaps most importantly, the network-level context in which neurons function. In this mini-review, we will provide a brief overview of recent insights into psychiatric disease-associated mouse models and behavior paradigms, focusing on those achieved by cellular resolution imaging of calcium dynamics in neural populations. We will then discuss how these experiments can support efforts within the pharmaceutical industry, such as target identification, assay development, and candidate screening and validation. Calcium imaging is uniquely capable of bridging the gap between two of the key resources that currently enable CNS drug discovery: genomic and transcriptomic data from human patients, and translatable, population-resolution measures of brain activity (such as fMRI and EEG). Applying this knowledge could yield real value to patients in the near future. |
| first_indexed | 2024-12-14T19:38:32Z |
| format | Article |
| id | doaj.art-62b0e1de51d341dbae3d993420d65927 |
| institution | Directory Open Access Journal |
| issn | 1664-0640 |
| language | English |
| last_indexed | 2024-12-14T19:38:32Z |
| publishDate | 2020-07-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Psychiatry |
| spelling | doaj.art-62b0e1de51d341dbae3d993420d659272022-12-21T22:49:46ZengFrontiers Media S.A.Frontiers in Psychiatry1664-06402020-07-011110.3389/fpsyt.2020.00713543685Calcium Imaging in Drug Discovery for Psychiatric DisordersSaurav SeshadriDaniel J. HoeppnerKatsunori TajindaThe past 5 years have seen a sharp increase in the number of studies using calcium imaging in behaving rodents. These studies have helped identify important roles for individual cells, brain regions, and circuits in some of the core behavioral phenotypes of psychiatric disorders, such as schizophrenia and autism, and have characterized network dysfunction in well-established models of these disorders. Since rescuing clinically relevant behavioral deficits in disease model mice remains a foundation of preclinical CNS research, these studies have the potential to inform new therapeutic approaches targeting specific cell types or projections, or perhaps most importantly, the network-level context in which neurons function. In this mini-review, we will provide a brief overview of recent insights into psychiatric disease-associated mouse models and behavior paradigms, focusing on those achieved by cellular resolution imaging of calcium dynamics in neural populations. We will then discuss how these experiments can support efforts within the pharmaceutical industry, such as target identification, assay development, and candidate screening and validation. Calcium imaging is uniquely capable of bridging the gap between two of the key resources that currently enable CNS drug discovery: genomic and transcriptomic data from human patients, and translatable, population-resolution measures of brain activity (such as fMRI and EEG). Applying this knowledge could yield real value to patients in the near future.https://www.frontiersin.org/article/10.3389/fpsyt.2020.00713/fullautismschizophreniasociabilitycognitiondrug discoverycalcium imaging |
| spellingShingle | Saurav Seshadri Daniel J. Hoeppner Katsunori Tajinda Calcium Imaging in Drug Discovery for Psychiatric Disorders Frontiers in Psychiatry autism schizophrenia sociability cognition drug discovery calcium imaging |
| title | Calcium Imaging in Drug Discovery for Psychiatric Disorders |
| title_full | Calcium Imaging in Drug Discovery for Psychiatric Disorders |
| title_fullStr | Calcium Imaging in Drug Discovery for Psychiatric Disorders |
| title_full_unstemmed | Calcium Imaging in Drug Discovery for Psychiatric Disorders |
| title_short | Calcium Imaging in Drug Discovery for Psychiatric Disorders |
| title_sort | calcium imaging in drug discovery for psychiatric disorders |
| topic | autism schizophrenia sociability cognition drug discovery calcium imaging |
| url | https://www.frontiersin.org/article/10.3389/fpsyt.2020.00713/full |
| work_keys_str_mv | AT sauravseshadri calciumimagingindrugdiscoveryforpsychiatricdisorders AT danieljhoeppner calciumimagingindrugdiscoveryforpsychiatricdisorders AT katsunoritajinda calciumimagingindrugdiscoveryforpsychiatricdisorders |